Short answer
Annexon, Inc. (ANNX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$44M
- +18.8% YoY
- EPS (diluted)
- −$0.23
- +37.8% YoY
Source: XBRL data from the Annexon, Inc. (ANNX) Q1 2026 10-Q on SEC EDGAR. USD.
Annexon, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No explicit new risk factor identified; filing text is truncated and lacks comparison with the prior 10-K
- Phase 3 ARCHER II execution risk, with global enrollment potentially requiring additional capital and delaying vonaprument commercialization
- Regulatory approval risk, as FDA and foreign authorities may reject ARCHER II data despite regulatory engagement
- Liquidity risk, with $225.0 million available funding planned through the second half of 2027
- Financing dilution risk, through a March 2026 at-the-market program allowing up to $150 million in common-stock sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Annexon, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.